HealthAffairs

Cookies Notification

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. <u>Find out more</u>. 🙀

Accept

RESEARCH ARTICLE

HEALTH AFFAIRS > VOL. 35, NO. 2: VACCINES

Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs

<u>Judith Kallenberg, Wilson Mok, Robert Newman, Aurélia Nguyen, Theresa Ryckman, Helen Saxenian, and</u> <u>Paul Wilson</u>

<u>AFFILIATIONS</u> >

Judith Kallenberg (jkallenberg@gavi.org) is head of policy at Gavi, the Vaccine Alliance, in Geneva, Switzerland.

Wilson Mok is senior manager of price forecasting at Gavi.

Robert Newman is Cambodia country director for the Centers for Disease Control and Prevention, in Phnom Penh. At the time this work was conducted, he was managing director of policy and performance at Gavi.

Aurélia Nguyen is director of policy and market shaping at Gavi.

Theresa Ryckman is a program officer at the Results for Development Institute, in Washington, D.C.

Helen Saxenian is a health economist and independent consultant in Bethesda, Maryland.

Paul Wilson is an assistant professor at the Mailman School of Public Health, Columbia University, in New York City.

PUBLISHED: FEBRUARY 2016 No Access https://doi.org/10.1377/hlthaff.2015.1079

🕖 View Article

Abstract

Gavi, the Vaccine Alliance, was created in 2000 to accelerate the introduction of new and underused vaccines in lower-income countries. The period 2000–15 was marked by the rapid uptake of new vaccines in more than seventy countries eligible for Gavi support. To stay focused on the poorest countries, Gavi's support phases out after countries' gross national income per capita surpasses a set threshold, which requires governments to assume responsibility for the continued financing of vaccines introduced with Gavi support. Gavi's

funding will end in the period 2016–20 for nineteen countries that have exceeded the eligibility threshold. To avoid disrupting lifesaving immunization programs and to ensure the long-term sustainable impact of Gavi's investments, it is vital that governments succeed in transitioning from development assistance to domestic financing of immunization programs. This article discusses some of the challenges facing countries currently transitioning out of Gavi support, how Gavi's policies have evolved to help manage the risks involved in this process, and the lessons learned from this experience.

TOPICS

VACCINES | CO-FINANCING | POPULATIONS | ECONOMIC BURDEN | COST SHARING | ACCESS TO CARE | MARKETS | COSTS AND SPENDING | LOW INCOME | INCOME LEVELS

Loading Comments...

HealthAffairs

1220 19th Street, NW, Suite 800 Washington, DC 20036 T 202 408 6801 F 301 654 2845 customerservice@healthaffairs.org

TOPICS

Access & Use Costs & Spending COVID-19 Health Equity Health Reform Leading To Health More Topics

CONTENT

Journal Forefront Scholar Briefs Events Podcasts Collected Works

INFORMATION FOR

Authors Request For Abstracts Reviewers Subscribers Advertisers Media News Room Funders **Event Attendees**

SERVICES & RESOURCES

Submit Content Subscribe Renew Membership Manage My Account Purchase Content Permissions Alerts Newsletter Sign Up Advertising Kit

HEALTH AFFAIRS

About Impact Report Terms & Conditions Privacy Policy Jobs At Health Affairs Fellowships Contact Us



Terms and conditions Privacy Project HOPE

Health Affairs is pleased to offer Free Access for low-income countries. Health Affairs gratefully acknowledges the support of many funders.

Health Affairs is an official journal of AcademyHealth.



SIXTY-FIVE YEARS OF HEALING PEOPLE AND TRANSFORMING LIVES Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.

Copyright 1995 - 2024 by Project HOPE: The People-to-People Health Foundation, Inc., eISSN 1544-5208.